FluoroPharma Medical Inc. is a molecular imaging company. The Company engages in the discovery, development and commercialization of proprietary diagnostic imaging products. FlouroPharma's initial focus is the development of positron emission tomography (PET) imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease.
500 Boylston Street
Boston, MA 02116